Pfizer (PFE) acquires Trillium Therapeutics (TRIL), Oncology is a hot sector

Shares of Trillium Therapeutics (TRIL) surged when Pfizer (PFE) announced that it would be acquiring shares in TRIL setting it at an astronomical valuation of $2.26 billion or $18.50 per share.

Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, which is emerging as a key immune checkpoint in hematological malignancies. TTI-622 and TTI-621 are novel, potentially best-in-class SIRPα-Fc fusion proteins that are currently in Phase 1b/2 development across several indications, with a focus on hematological malignancies.

The proposed acquisition of Trillium is to be completed by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) and subject to customary closing conditions, including approval of 66⅔% of the votes cast by Trillium shareholders, voting together as one class, at a special meeting of Trillium and approval of 66⅔% of the votes cast by Trillium shareholders and warrant holders, voting together as one class, at a special meeting of Trillium.   Completion of the acquisition is also subject to court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature.

Pfizer’s financial advisors for the transaction are BofA Securities, Inc., with Ropes & Gray LLP and Norton Rose Fulbright Canada LLP acting as its legal advisors. Centerview Partners LLC served as Trillium’s financial advisor, while Goodwin Procter LLP and Baker McKenzie LLP (Canada) served as its legal advisors.

Pfizer to get full approval of COVID-19 coronavirus vaccine

In addition to this acquisition, Pfizer is slated to get full FDA approval of its COVID-19 vaccine this week. This will empower businesses and universities to require vaccinations and tip hesitant Americans toward getting the jab. Until now, the Pfizer shot has been administered under an emergency use authorization, though experts continue to emphasize that it is safe and effective.